PHI with Seafood allergy
How does this condition affect your private health insurance?
Meeresfrüchteallergie (Seafood allergy) is an immune system overreaction to proteins found in shellfish (e.g., shrimp, crab, lobster, oysters) or finned fish. Symptoms range from mild, such as hives, swelling, itching, and digestive issues like vomiting or diarrhea, to severe, including difficulty breathing, a sudden drop in blood pressure, and anaphylaxis, a potentially life-threatening reaction. The body mistakenly identifies harmless proteins as threats, triggering a release of histamines and other chemicals. Diagnosis involves skin prick tests, blood tests (IgE levels), and patient history. Strict avoidance of seafood is the primary management, and emergency epinephrine auto-injectors are crucial for those with severe reactions.
PKV Risk Assessment
Impact on Your Insurance Policy
Duration of Illness (Initial)
Several minutes to a few hours, typically resolving within a day with appropriate treatment.
Duration of Illness (Lifetime)
Chronic, usually a lifelong condition requiring ongoing avoidance of allergens.
Cost of Treatment (Initial)
50-500 EUR (ranging from over-the-counter antihistamines to emergency room visits and epinephrine).
Cost of Treatment (Lifetime)
500-2000 EUR (including regular replacement of epinephrine auto-injectors, specialist consultations, and ongoing dietary management).
Mortality Rate
Low (less than 0.1%), primarily due to severe anaphylaxis if not treated promptly with epinephrine.
Risk of Secondary Damages
Low for significant physical damage (e.g., rare anoxic brain injury from prolonged anaphylaxis); moderate for psychological impact (anxiety, fear of accidental exposure, social limitations).
Probability of Full Recovery
Low (less than 10%), especially for adult-onset cases; higher probability of outgrowing in early childhood, but still not common.
Underlying Disease Risk
High, often co-occurs with other atopic conditions such as allergic rhinitis, asthma, atopic dermatitis, or other food allergies.